Immunotherapy, as the most cutting-edge cancer treatment program, can more accurately predict the effect of immunotherapy through the biomarkers of four classes of immunotherapy, including PD-L1 expression, TMB, MSI detection, and TIL detection. This evidence concerns the gene CD274 and cancer.